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Abstract: 
Objective: To review glucose-lowering efficacy and changes in renal function associated with 
GLP-1 receptor agonists and SGLT2-Inhibitors among patients with chronic kidney disease (CKD) 
and type 2 diabetes mellitus (T2DM).  
Data Sources: A literature search of MEDLINE and Cochrane databases was performed from 
2000 to March 2018 using search terms: SGLT2 inhibitors, sodium glucose co-transporter 2, 
canagliflozin, empagliflozin, dapagliflozin, glucagon-like peptide-1 receptor agonists, GLP-1, 
exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and chronic kidney 
disease. References of identified articles were also reviewed. 
Study Selection and Data Extraction: English-language studies investigating glucose-lowering 
endpoints and/or changes in renal function with a U.S. approved SGLT2 inhibitor or GLP-1 
receptor agonist were included. 
Data Synthesis: GLP-1 agonists and SGLT2-Inhibitors effectively lower glucose in patients with 
T2DM and CKD. Both agents have demonstrated short-term renoprotective effects by slowing 
progression of albuminuria and decreasing urine albumin-to-creatinine values. 
Relevance to Patient Care and Clinical Practice: This review highlights the glucose-lowering 
efficacy and reported renal benefits of GLP-1 agonists and SGLT2-Inhibitors when used in 
patients with T2DM and CKD. Given that these comorbidities are associated with increased 
cardiovascular risk, we believe that these agents should be the preferred add-on agents in most 
patients with uncontrolled T2DM and CKD.  
Conclusions:  In patients with T2DM and CKD, GLP-1 agonists and SGLT2-Inhibitors are effective 
in lowering glucose, preventing progression of worsening albuminuria, and may reverse the 
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level of albuminuria. Ongoing studies will provide additional information as to whether these 
agents will become standard of care in treating patients with T2DM and CKD. 
 
 
 
Introduction:  
Chronic kidney disease (CKD), defined as reduced estimated glomerular filtration rate (eGFR) 
and/or presence of increased albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) for at 
least 3 months, is a common comorbidity of diabetes mellitus (DM).1 While CKD may result 
from multiple etiologies, long-term uncontrolled DM is a major risk factor for diabetic kidney 
disease, as well as the most common cause of CKD and the leading cause of end-stage-renal 
disease globally.2,3  The most recent estimates from the United States Renal Data System 
(USRDS) report that approximately 40% of patients with CKD also have concomitant DM.4  
Given that DM and CKD are both associated with increased morbidity and mortality, multi-
interventional approaches are recommended to reduce the progression of worsening 
albuminuria and kidney dysfunction, as well as lower risk of cardiovascular events. Such 
approaches include achieving blood pressure <130/80 mm Hg,1,5 use of angiotensin converting 
enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with CKD and 
albuminuria, as well as maintaining glycemic control.1,5   
 
Patients with type 2 DM (T2DM) may achieve glycemic control with a combination of oral and 
injectable medications. Current standards for treating T2DM recommend choosing additional 
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antihyperglycemic therapies based on several patient-specific factors, including efficacy of 
lowering hemoglobin A1C (A1C), cost, risk of hypoglycemia, and potential for weight gain. 
Metformin remains the preferred first agent for most patients with T2DM due to effective A1C-
lowering, low hypoglycemia risk, neutral weight gain, and low cost. Metformin is primarily 
renally eliminated, thus contraindicated in patients with an eGFR <30 ml/min/1.73m2.5 In 
patients with T2DM and CKD, renal function must also be considered as many of the available 
second-line antihyperglycemic agents require dose reduction in the setting of reduced renal 
function, or are not recommended for continued use in patients with eGFR <45 ml/min/1.73m2 
(Table 1). 
 
Recent cardiovascular outcomes trials (CVOT) have reported reduced risk of major 
cardiovascular events with select oral antihyperglycemic agents. Trials evaluating sodium-
glucose co-transporter-2 inhibitors (SGLT2-I) empagliflozin and canagliflozin, and glucagon-like 
peptide-1 receptor agonist (GLP-1RA), liraglutide, each reported reduced risk of a primary 
composite endpoint of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke 
compared to placebo when added to standard antihyperglycemic treatment in patients with 
T2DM.6–8  Each trial included a subset of patients with CKD and reported on prespecified renal 
outcomes, although not as a primary study endpoint. In the EMPA-REG trial,6 26% of patients 
had an eGFR <60 ml/min/1.73m2 and nearly 40% had some degree of albuminuria. Compared to 
placebo, empagliflozin was associated with a 38% reduction in progression to 
macroalbuminuria and 44% reduction in doubling serum creatinine. In the CANVAS studies8, 
30.2% had some degree of albuminuria, the majority defined as microalbuminuria. Improved 
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renal outcomes associated with canagliflozin included a 27% reduced risk of albuminuria 
progression, and lower risk of a composite renal outcome including consistent 40% reduction in 
eGFR, need for renal replacement therapy, or renal death. Regression of albuminuria also 
occurred more frequently in those who received canagliflozin compared to placebo. Lastly, the 
LEADER7 trial included 21% of subjects with eGFR 30-59 ml/min/1.73m2, and even included a 
small sample of patients (2.4%) with eGFR<30 ml/min/1.73m2. The composite renal endpoint of 
new macroalbuminuria or doubling of serum creatinine with eGFR <45 ml/min/1.73m2, need 
for renal replacement therapy, or renal death was reduced by 22% in subjects who received 
liraglutide vs placebo, but occurred at relatively low rates in each group (1.5% vs 1.9%, 
respectively).  
 
Given that canagliflozin, empagliflozin, and liraglutide all demonstrated lower risk of major 
cardiovascular events, as well as potential improvements in renal outcomes, these agents may 
be preferred therapies in patients with T2DM and CKD. The objective of this article is to review 
available evidence assessing the efficacy and potential renoprotective effects of SGLT2-I and 
GLP-1RAs in patients with CKD and T2DM. 
 
 
Methods  
Data Sources 
A search was conducted using PubMed and Cochrane databases to identify studies from 2000 
to March 7, 2018 pertaining to the safety and efficacy of SGLT2-I and GLP-1RA among patients 
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with CKD. Mesh terms and keywords used in the search included, “SGLT2 inhibitors”, “sodium 
glucose co-transporter 2”, “canagliflozin”, “empagliflozin”, “dapagliflozin”, “Glucagon-Like 
Peptide-1 Receptor/agonists”, “GLP-1”, “exenatide”, “liraglutide”, “albiglutide”, “dulaglutide”, 
“lixisenatide”, “semaglutide”, “kidney disease”, and “chronic kidney disease”. PubMed search 
filters were applied for English language, humans, and adults aged ≥18 years. References of 
identified articles were reviewed to identify any additional studies not found in the initial 
search. In order to limit results to only clinical trials, the search filter for clinical queries was 
applied.9 Article selection and screening process is depicted in Figure 1.  
 
Study Selection 
Studies were included if they reported outcomes related to glucose-lowering efficacy and/or 
renal endpoints for U.S. approved SGLT2-I or GLP-1RA in a study population of T2DM and CKD, 
defined as an eGFR <60 ml/min and/or urine albumin-to-creatinine ratio >30 mg/g (or 
equivalent). Pre-post studies were eligible if they reported baseline and follow up changes. 
Trials including patients with CKD and normal kidney function could be considered if full data 
for the CKD population was presented separate from the study population as a whole. 
Secondary analysis of a CKD populations from primary trials were also eligible. Published 
abstracts, editorials, and letters to the editor were not included in this review. 
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Results 
Potential articles were reviewed by three authors (MK, JL, AH) to determine eligibility. Eight 
studies met our inclusion criteria and are summarized in Table 2. Three studies evaluated 
liraglutide, while five studies evaluated SGLT2-I (canagliflozin, dapagliflozin, and empagliflozin).  
 
Of the eight included studies, all but one was a randomized-control trial10. Five studies 
employed a placebo group against active treatment (SGLT2-I or GLP-1RA)11–15, one study 
compared SGLT2-I or to glimepiride treatment16, and one study compared GLP-1RA added to 
insulin therapy vs insulin therapy alone17.  Efficacy of SGLT2-I or GLP-1RA was assessed by 
change in A1C in seven studies10–15,17, along with change in fasting plasma glucose in five 
studies.11–15 Renal endpoints of change in eGFR were assessed in five studies10,11,13,14,16, and all 
eight studies assessed change in urine protein-to-creatinine (UPCR) or urine albumin-to-
creatinine ratio (UACR).  
 
 
Glucagon-like peptide-1 (GLP-1) receptor agonists 
Currently there are six GLP-1RA available in the US, including exenatide, liraglutide, lixisenatide, 
dulaglutide, semaglutide, and albiglutide. GLP-1RA lower glucose by several mechanisms, 
including increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, 
and increasing satiety. All GLP-1RA are indicated as an adjunct to diet and exercise to improve 
glycemic control in adults with T2DM. Liraglutide now carries an additional indication for 
reduced risk of major cardiovascular events in adults with T2DM and clinical cardiovascular 
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disease.  Renal dose adjustment is not required for most GLP-1RA, except exenatide and 
lixisenatide (Table 1). Exenatide is not indicated in patients with eGFR <30mL/min/1.73m2, 
while lixisenatide should not be used in patients with eGFR <15mL/min/1.73m2.5 
 
Efficacy and Renal Effects of GLP-1RA in Patients with CKD 
The Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in 
Patients With T2DM and Moderate Renal Impairment (LIRA-RENAL) trial evaluated liraglutide 
efficacy and safety over a 26-week period when added on to existing antihyperglycemic therapy 
in patients with uncontrolled T2DM and moderate renal impairment11. This double-blind, 
placebo-controlled trial included 279 patients with a mean age approximately 67 years and an 
A1C of ~8%. Patients were randomized to daily liraglutide or placebo subcutaneous injection. 
Approximately 43% of patients in each group had an eGFR 30-44 mL/min/1.73m2, 56% of 
patients had an eGFR of 45-59 mL/min/1.73m2, and mean UACR was 55.5 mg/g for the 
liraglutide group and 69.8 mg/g for the placebo group. The primary endpoint was change in 
baseline A1C to week 26; changes in fasting plasma glucose (FPG) from baseline to week 26 
were also assessed. After 26 weeks, A1C was reduced -1.05% in the liraglutide group vs. -0.38% 
in the placebo group (p<0.0001).  Estimated mean change in FPG from baseline to 26 weeks 
was -22.0 mg/dL with liraglutide vs. -10.3 mg/dL with placebo (p=0.036). Changes in renal 
function (eGFR and UACR) were measured from baseline to 26 weeks. The mean observed 
change in eGFR after 26 weeks was -0.35 mL/min/1.73m2 in the liraglutide group versus 0.37 
mL/min/1.73m2 in the placebo group, which resulted in an estimated treatment ratio of 0.98 
(p=0.36). The ratio of UACR values at week 26 compared to baseline were 0.87 with liraglutide, 
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compared to 1.05 with placebo, however this difference was not statistically significant 
(p=0.19). The study concluded that liraglutide is effective in improving glycemic control, without 
affecting renal function.11  
 
A single-arm study of 23 Japanese patients with T2DM evaluated the A1C-lowering effect and 
progression of diabetic nephropathy (DN) and proteinuria following 12-month treatment with 
liraglutide.10  Patients had a mean age of 58.2 years, mean A1C of 7.4% at baseline and all 
patients had overt DN (defined as UPCR >0.5 g/g) prior to study entry, with baseline UPCR of 
2.53 g/g (or 2530 mg/g). No comparator arm was used in this study, rather a pre/post design. A 
significant decrease in A1C was observed at all time points. Baseline A1C was reduced from 
7.4% to 7.0% after 1 month (p<0.001), 6.6% by month 6 (p<0.001), and 6.9% by month 12 
(p<0.05). Baseline UPCR decreased to 1.62 g/g at 1 month (p<0.001), 1.45 g/g at 6 months 
(p<0.001), and finally 1.47 g/g at 12 months (p<0.01). The study also found a strong correlation 
between baseline proteinuria and changes in proteinuria after 12 months of liraglutide therapy 
(r=0.84, p<0.0001). Changes in eGFR were minimal over the 12-month study period, as eGFR 
decreased slightly from 58.2 mL/min/1.73m2 at baseline to 56.9 mL/min/1.73m2 after 12 
months. Annual rates of eGFR decline were improved with liraglutide, decreasing from -6.6 
mL/min/1.73m2/year prior to liraglutide initiation, to -0.33 mL/min/1.73m2/year (p=0.003) after 
one year of liraglutide. Thus, with a significant decline in proteinuria and improved eGFR 
decline, authors concluded that for patients with T2DM and overt DN, addition of liraglutide is 
useful for decreasing A1C as well as slowing the progression of DN.10        
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 A third single-center, open-label trial evaluated changes in several cardiometabolic markers, 
including albuminuria, with liraglutide in patients with T2DM treated with insulin.17 Seventeen 
patients were randomized to either liraglutide titrated up to 0.9 mg/day plus insulin (8 patients) 
or insulin treatment only (9 patients). In addition to insulin, patients in each cohort were also 
receiving oral antihyperglycemic agents. Mean age was 59 years and a greater proportion of 
males (63%) were randomized to receive liraglutide compared to the control group (33%). 
Mean eGFR was >60 ml/min/1.73m2 in both groups, but albuminuria was present in both study 
cohorts. Mean baseline A1C was 8.2% in the liraglutide group and 7.9% in the placebo group, 
and both groups were receiving daily insulin doses of about 0.5 units/kg/day. Mean A1C and 
weight were significantly reduced in the liraglutide group after 12, 24, and 36 weeks of 
treatment. At week 24, baseline A1C values had fallen from 8.2% to 7.5% in patients receiving 
liraglutide compared with an increase from 7.9% to 8.1% in the control group (p=0.0035). No 
data on fasting or post-meal plasma glucose were reported. Mean UACR levels at baseline were 
220 mg/g in the liraglutide group and 254 mg/g in the control group, consistent with 
albuminuria. Compared to placebo, liraglutide was associated with significantly decreased 
mean UACR at week 12 (343 mg/g vs 76 mg/g; p=0.050), week 24 (310 mg/g vs 91 mg/g; 
p=0.016), and week 36 (226 mg/g vs 32 mg/g; p=0.022). The authors concluded that when 
added to baseline insulin therapy in patients with T2DM, liraglutide favorably improves 
glycemic control, body weight, inflammatory markers, and albuminuria.17 
 
   
Sodium-Glucose Co-transporter Type 2 (SGLT2) inhibitors 
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Currently four SGLT2-I (canagliflozin, dapagliflozin, empagliflozin, and most recently 
ertugliflozin) are approved to improve glucose in adults with T2DM as adjunct to diet and 
exercise. As a class, the SGLT2-I increase urinary glucose excretion by blocking the reabsorption 
of glucose in the renal proximal tubule. As SGLT2-I exert their effect in the kidneys, there are 
specific dose adjustments based upon renal function according to each medication’s prescribing 
information (Table 1). Renal function should be assessed prior to initiation of SGLT2-I and 
periodically thereafter to ensure adequate renal function. The recommended eGFR range for 
continued SGLT2-I use varies among agents, but all are contraindicated when eGFR <30 
mL/minute/1.73 m2.5  
 
Efficacy and Renal Effects of SGLT2-I in Patients with CKD 
The Efficacy and safety of empagliflozin added to existing anti-diabetes treatment in patients 
with T2DM and chronic kidney disease (EMPA-REG-RENAL) trial was a multicentered, 
randomized, double-blind, parallel-group trial, designed to assess the efficacy and safety of 
empagliflozin in patients with CKD stages 2-4 and T2DM.12 Full efficacy and renal outcomes data 
were available for CKD stages 2 (n=290) and 3 (n=374), but not stage 4 (n=74). Patients with 
CKD stage 3 (eGFR ≥30 to <60 mL/min per 1.73 m2) were randomized to receive empagliflozin 
25 mg or placebo for 52 weeks. Patients in this CKD subgroup had a mean age of 64.9 years, 
and baseline eGFR of 44.9 mL/min per 1.73 m2. The primary efficacy endpoint was change in 
A1C from baseline to week 24. Changes in FPG, body weight, and BP were also examined as 
secondary endpoints. Changes in eGFR and UACR throughout the study were evaluated as 
safety endpoints. 
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In the stage 3 CKD subgroup, the adjusted mean change in A1C from baseline to week 24 was    
-0.42% for empagliflozin 25 mg vs. placebo (p<0.0001). The A1C-lowering effect remained at 
week 52, with mean A1C reduction of -0.44% compared to placebo (p<0.0001). Adjusted 
treatment differences for empagliflozin vs placebo were also significantly lower for FPG at both 
24 weeks (-1.1 mmol/L; p<0.001) and 52 weeks (-0.7 mmol/L; p=0.0037). In addition to reduced 
A1C and FPG, there was also a significant decrease in body weight and BP with empagliflozin 
versus placebo.  Compared to placebo, a greater reduction in UACR from baseline to 52 weeks 
was reported with empagliflozin (–183.78 mg/g; p=0.0031). Although not a specified endpoint 
of this trial, fewer patients randomized to empagliflozin progressed from normal UACR to 
microalbuminuria (UACR 30-299 mg/g) compared to placebo (12.2% vs. 22.2%) and from 
microalbuminuria to macroalbuminuria (UACR ≥300 mg/g) (2.0% vs. 11.4%). Additionally, a 
greater proportion of patients with baseline macroalbuminuria improved to microabluminuria 
with empagliflozin (32.6%) compared to those who received placebo (8.6%). This study was one 
of the first trials to report improved glycemic control and improved albuminuria status in 
patients with T2DM and CKD.12  
          
A second multicenter placebo-controlled, double-blind clinical trial evaluated the efficacy and 
safety of dapagliflozin in patients with T2DM and moderate renal impairment (eGFR 30 to 59 
mL/min per 1.73m2) and included a small percentage of patients with eGFR ≥60 mL/min per 
1.73m2 (4.4%) and eGFR <30 mL/min per 1.73m2 (4.0%) at baseline. Patients were similar in 
baseline characteristics for each study group. Mean age ranged from 66-68 years, and baseline 
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A1C differed by study group and ranged from 8.22% to 8.53%. All patients had a mean UACR 
>60 mg/g, and over two-thirds of patients had diagnosed DN at baseline. Patients were 
randomized to receive dapagliflozin 5 mg, 10 mg, or placebo for at least 24 weeks in addition to 
other pre-enrollment antihyperglycemic therapies. Patients who completed the first 24 weeks 
of therapy were eligible to continue for an additional 28 weeks, then an additional extension 
period of 52 weeks (total of 104 weeks). There were 252 patients randomized, 202 entered the 
study for an additional 28 weeks, and 139 patients completed 104 weeks of the extension 
period. The primary endpoint was mean change in A1C from baseline to 24 weeks; change in 
FPG from baseline to week 24 was also evaluated. At the end of week 24, there was no 
statistically significant difference in the mean change in A1C for dapagliflozin 5 mg compared to 
placebo (-0.41% vs. -0.32%; p=0.561) or dapagliflozin 10 mg vs placebo (-0.44% vs. -0.32%; 
p=0.435).  Both doses of dapagliflozin reduced FPG from baseline to 24 weeks more than 
placebo, however statistical significance was evaluated. In a post-hoc analysis of baseline CKD 
status, dapagliflozin produced a larger reduction in the adjusted A1C change and FPG in 
patients with CKD stage 3A compared to stage 3B from baseline to week 24 versus placebo.  
Numerically lower reductions in eGFR from baseline to week 24 were reported in the placebo 
group (-0.25 mL/min/1.73m2) compared to dapagliflozin 5 mg (-2.38 mL/min/1.73m2) and 10 
mg (-4.80 mL/min/1.73m2). By week 104, changes in eGFR were similar between placebo (-2.38 
mL/min/1.73m2) and dapagliflozin 5 mg (-1.71 mL/min/1.73m2) and 10 mg (-3.50 
mL/min/1.73m2), however no statistical significance was reported for either time period. 
Patients receiving dapagliflozin were more likely to experience a shift to a lower UACR category 
than patients receiving placebo (22.6% vs. 10.7%). Lastly, fewer patients receiving dapagliflozin 
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5 or 10 mg compared to placebo experienced a UACR value >1800 mg/g during the 104-week 
treatment (10.8%, 9.5%, and 13.3%, respectively). The results of this trial contrast to those from 
the EMPA-REG-RENAL trial in that dapagliflozin did not demonstrate significant A1C-lowering 
efficacy among patients with T2DM and CKD. Dapagliflozin did appear to improve UACR more 
than placebo, but again was not a primary endpoint of this trial. 
          
 
Three trials have evaluated the efficacy and safety of canagliflozin in patients with T2DM and 
CKD. The first study published in 2013 was a randomized, double-blind, placebo-controlled, 
phase 3 trial conducted across 89 centers in 19 countries.14 The study included 269 patients 
with T2DM and stage 3 CKD (eGFR ≥30 to <50 mL/min/1.73m2). Patients had a mean age of 68.5 
years and A1C of 8.0%. Baseline mean was eGFR 39.4 mL/min/1.73m2 with mean UACR of 30.0 
mg/g. Patients were randomized to canagliflozin 100 mg, 300 mg, or placebo daily to assess the 
change in A1C at week 26 compared to baseline. Both doses of canagliflozin (100 and 300 mg) 
produced a significant reduction in mean A1C from baseline in arms compared to placebo (-
0.33% vs. -0.03%; p<0.05) and (-0.44% vs. -0.03%; p<0.01), respectively. Changes in FPG from 
baseline to week 26 were numerically lower for both canagliflozin 100 vs placebo, although 
neither reached statistical significance. Each study group experienced a decrease in eGFR, but 
reductions were larger in both the canagliflozin 100 and 300 mg groups compared to placebo 
(mean percent changes of -9.1%, -10.1%, and -4.5% respectively). There was also an increase in 
blood urea nitrogen (BUN) with both canagliflozin arms compared to placebo. The reductions in 
eGFR and increased BUN with canagliflozin arms occurred early and trended back towards 
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baseline by week 26. A lower proportion of patients treated with canagliflozin 100 and 300 mg 
had a progression of albuminuria from baseline to week 26 compared to placebo (5.1, 8.3, and 
11.8% respectively). Lastly, treatment with canagliflozin 100 and 300 mg was associated with 
greater median percent reductions in UACR from baseline to week 26 compared to placebo        
(-29.9%, -20.9%, and -7.5%, respectively), although no statistical significance was calculated. 
 
As a follow-up extension study, 229 of the 269 patients that completed the first 26 weeks of 
therapy continued for an additional 26 weeks to evaluate the efficacy and safety of canagliflozin 
at week 52.13 At week 52, changes in A1C from baseline were numerically lower for 
canagliflozin 100 mg vs. placebo (-0.19% vs. 0.07%) and canagliflozin 300 mg vs. placebo (-
0.33% vs. 0.07%). Confidence intervals (95% CI) for calculated differences between canagliflozin 
100 mg and 300 mg showed that only canagliflozin 300 mg significantly reduced A1C from 
baseline to week 52. Similar to changes in FPG from the 26-week study, changes at 52 weeks 
were numerically lower with both doses of canagliflozin but did not achieve statistical 
significance. Decreases in eGFR at week 52 were seen with canagliflozin 100 and 300 mg 
compared with placebo (–2.1, –4.0 and –1.6 ml/min/1.73m2, respectively). Assessing changes in 
UACR from baseline to week 52 showed that placebo was associated with a 19.7% increase in 
UACR, compared to a -16.4% decrease with canagliflozin 100 mg and -28.0% with canagliflozin 
300 mg. Similar to the results seen at the 26-week time period, the proportion of patients 
progressing from normal UACR to albuminuria was lower with canagliflozin 100 and 300 mg 
(10.3%, 14.7%, respectively) compared to placebo (17.1%). These two trials provide evidence 
that canagliflozin is associated with a clinically relevant A1C reductions, and the potential to 
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improve UACR in patients with T2DM and CKD who require additional glucose-lowering 
therapy. 
         
The most recent study of canagliflozin in patients with T2DM and CKD was a secondary analysis 
of a previous multicentered clinical trial of patients randomized to either canagliflozin 100 or 
300 mg daily or glimepiride titrated up to 8 mg daily. Data for a subgroup of patients (n=230) 
with UACR ≥30 mg/g at baseline was reported separate from the overall study cohort. Baseline 
characteristics for the CKD subgroup were similar to the overall study group. Mean age ranged 
from 55.6 to 58.5 years, and baseline A1C was 7.9% in patients randomized to glimepiride or 
canagliflozin 100 mg, and 8.0% in the canagliflozin 300 mg group. Mean eGFR at baseline 
ranged from 86.5 to 91.1 ml/min/1.73m2, similar to the overall study population. Mean UACR 
varied between the study groups of the CKD patients, with the lowest UACR (56.5 mg/dL) in 
canagliflozin 100 mg group and the highest UACR value (75.2 mg/dL)  in the canagliflozin 300 
mg group. Endpoints reported separately for this subgroup of CKD patients included 30% 
decline in eGFR and percent reduction in UACR over a 2-year period. No data on A1C-lowering 
between glimepiride and canagliflozin groups were reported for the CKD subgroup. However, in 
the CKD subgroup, significant reductions in UACR from baseline were reported with 
canagliflozin 100 mg (-31.7%;P=0.01) and canagliflozin 300 mg (-49.3%; p<0.001) versus 
glimepiride. Additionally, decline in eGFR was measured during the 2-year trial period. In 
patients with baseline UACR >30 mg/g, calculated hazard ratios (HR) for 30% eGFR decline were 
lower for canagliflozin 100 mg (HR=0.37; p=0.03) and canagliflozin 300 mg (HR=0.69; p=0.33) 
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versus glimepiride. This trial provides evidence that canagliflozin may be more effective in 
slowing progression of DN compared to glimepiride. 
 
Currently, the Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes 
in Participants With Diabetic Nephropathy (CREDENCE) clinical trial is prospectively evaluating 
renal and cardiovascular endpoints with canagliflozin vs placebo in patients with T2DM and CKD 
stage 2 or 3 with UACR >300 mg/g, already treated with maximally tolerated ACE-i or ARB. 
(NCT02065791). This trial’s primary composite endpoint is time to first occurrence of end-stage 
kidney disease (ESKD), doubling of serum creatinine, renal or cardiovascular death. Expected 
trial duration is 5.5 years.18 
 
 
Relevance to Patient Care and Clinical Practice 
Current standard of care for preventing progression of CKD includes controlling BP and glucose, 
as well as use of renin-angiotensin inhibitors. Several oral and injectable antihyperglycemic 
agents are available to improve glucose in patients with T2DM. Current standards of care 
promote a patient-centered approach when selecting additional glucose-lowering medication, 
considering risk of hypoglycemia, weight gain, adverse effects, and most recently cardiovascular 
and renal effects.5 Cardiovascular outcomes trials have reported reduced cardiovascular risk 
with liraglutide, canagliflozin, and empagliflozin and reported positive changes in composite 
renal endpoints, although in a predominately non-CKD population. Whether the cardiovascular 
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or renal benefits of these medications translate to patients with CKD has not been 
prospectively evaluated in long-term clinical trials.  
 
Our literature review identified eight studies that reported efficacy and/or assessment of renal 
changes in patients with CKD and T2DM. Available studies suggest that in patients with CKD, 
both GLP-1RA and SGLT2-I are associated with A1C reductions similar to patients without CKD. 
A recent meta-analysis of 38 randomized controlled trials  including nearly 24,000 patients with 
T2DM treated with one of three SGLT2-I (canagliflozin, dapagliflozin, or empagliflozin) reported 
significant A1C reductions of -0.6% to -0.9%, compared to placebo.19 Similarly, a meta-analysis 
of available GLP-1RA included 34 trials and over 14,000 patients with T2DM reported that GLP-
1RA have the ability to lower A1C -0.55% to -1.21% versus placebo.20  From our review, there is 
evidence that liraglutide and several SGLT2-I positively impact albuminuria either by reducing 
UACR in patients with micro- or macroalbuminuria, or by preventing progression to 
albuminuria. Both liraglutide and the SGLT2-I studied produce a small decrease in eGFR 
compared to baseline, which may not be clinically significant. This small decrease in eGFR 
would likely be outweighed by the positive renal effects of preventing or reversing albuminuria. 
 
The precise mechanism by which SGLT2-I and GLP-1RA exert their potentially renoprotective 
benefits is currently unknown. Potential mechanisms for improving albuminuria may be 
multifactorial, including: increased natriuresis, reduced intraglomerular pressure, reduced renal 
hyperfiltration, as well as pleiotropic effects such as anti-inflammatory effects.21,22 Both 
antihyperglycemic classes have been shown to inhibit a sodium-hydrogen exchanger protein 
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(NHE3) located in the proximal tubule, which may be responsible for the natriuretic effect and 
excreting excess sodium.21,22 While tight glucose control is associated with reduced risk for 
developing diabetic nephropathy, it is unlikely that the renal benefits of SGLT2-I and GLP-1RA 
are entirely due to glucose lowering. Studies as short as 26 weeks demonstrated improvements 
in albuminuria despite minimal A1C reductions. Even in long-term CVOT, the improvement in 
glycemic control was modest, and not likely to be the sole contributor to improving renal 
outcomes or reducing cardiovascular risk. While both GLP-1RA and SGLT2-I are also associated 
with reductions in body weight and BP, these effects are modest and may not fully explain the 
cardiovascular and renal benefits seen reported in our review. Perhaps the culmination of 
reduced glucose, BP, natriuresis, and anti-inflammatory effects lead to the observed 
improvements in albuminuria. 
 
Regardless of the mechanism, these agents have demonstrated glucose-lowering and improved 
albuminuria effects in patients with T2DM and CKD. Additionally, long-term CVOTs trials have 
reported reduced cardiovascular risk in patients at high risk of cardiovascular disease. While not 
without potential adverse effects, we believe that GLP-1RA and SGLT2-I should become first-
line agents (in addition to renin-angiotensin inhibitors) in patients with T2DM and CKD, a 
population at increased risk for CV mortality. Ongoing clinical trials prospectively evaluating 
SGLT2-I will provide definitive information regarding renoprotective benefits in patients with 
T2DM and CKD, already receiving standard of care. A meta-analysis of available data assessing 
positive albuminuria changes effects of SGLT2-I and GLP-1RA would be a valuable endeavor.  
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Conclusion 
Our review highlights that both SGLT2-I and GLP-1RA can be used in patients with T2DM and 
CKD to improve glycemic control. Three SGLT2-I and the GLP-1RA liraglutide reduced A1C and 
improved or prevented albuminuria in patients with CKD and T2DM. Current ADA standards 
now recommend consideration of renal effects when choosing antihyperglycemic therapy in 
patients with T2DM and note benefits of three agents on progression to diabetic nephropathy. 
Prospective trials are needed to confirm the observed renoprotective effects in patients with 
CKD and T2DM. If future trials are successful, SGLT2-I and/or GLP-1RA should join renin-
angiotensin inhibitors as recommended treatment in patients with uncontrolled T2DM and CKD 
to slow progression of diabetic kidney disease.  
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Table 1: Renal dose adjustments for antihyperglycemic agents 
Biguanides 
Metformin 
eGFR 30-44  
 
Do not initiate  
Consider 50% dose reduction if 
previously treated 
eGFR <30 Use is contraindicated 
DPP4-inhibitors 
Alogliptin 
CrCl ≥30-59 12.5 mg daily 
CrCl ≥15-29 6.25 mg daily 
ESRD (CrCl <15 or 
requiring 
hemodialysis) 
6.25 mg daily  
Saxagliptin 
eGFR <45 2.5 mg daily  
ESRD requiring 
hemodialysis  
2.5 mg daily 
Sitagliptin 
eGFR ≥30-44 50 mg daily 
eGFR <30 25 mg daily 
ESRD requiring 
hemodialysis or 
peritoneal dialysis 
25 mg daily 
SGLT2-Inhibitors  
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Canagliflozin 
eGFR 45-59  100 mg daily (maximum dose) 
eGFR ≥30-44 
Do not initiate 
Discontinue if eGFR persistently <45 
eGFR<30 Use is contraindicated 
Dapagliflozin 
eGFR 30-59 
Do not initiate  
Discontinue if eGFR persistently <60 
eGFR <30 Use is contraindicated 
Empagliflozin 
eGFR 30-44 
Do not initiate 
Discontinue if eGFR persistently <45 
eGFR<30 Use is contraindicated 
Ertugliflozin 
eGFR 30-59 
Do not initiate 
Discontinue if eGFR persistently <60 
eGFR <30  Use is contraindicated 
GLP-1 receptor agonists 
Exenatide CrCl <30 or ESRD  Use not recommended 
Lixisenatide eGFR <15  Use not recommended 
Alpha-glucosidase inhibitor 
Acarbose eGFR <30  Use not recommended 
Miglitol eGFR <25  Use not recommended 
CrCl= creatinine clearance (ml/min); eGFR= estimated glomerular filtration rate 
(ml/min/1.73m2); ESRD = end-stage renal disease. 
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Figure 1: Study selection flowchart 
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Table 2: Summary of trials of GLP-1 Receptor agonists and SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease 
Study Study design 
Number  
of pts 
Baseline renal 
function (eGFR-
mL/min/1.73m2) or 
UACR) 
Study 
duration 
Treatment 
groups  
Efficacy (change in 
A1C) 
Renal endpoints 
assessed 
GLP1 Receptor Agonists 
Davies et 
al. 2016 
Randomized, 
double-
blind, and 
placebo-
controlled 
tiral 
279 
Baseline eGFR: 
Liraglutide: 45.4 
ml/min/1.73m2   
 
Placebo: 45.5 
ml/min/1.73m2  
 
Baseline UACR: 
26 weeks 
Liraglutide 
titrated up 
to 1.8 mg 
daily versus 
placebo 
Change in A1C from 
baseline to week 26: 
Liraglutide vs 
placebo: 
   
(-1.05% vs. 
-0.38%; p<0.0001) 
 
 
Estimated ratio of 
eGFR at week 26 to 
baseline: 
 
Liraglutide and 
placebo (0.99 vs. 
1.01; p=0.36)  
 
 
 2 
Liraglutide: 55.5 mg/g 
Placebo: 69.8 mg/g 
Change in FPG 
(mg/dL) from 
baseline to week 26: 
 
Liraglutide vs. 
placebo (-22.0 vs.   
-10.3; p=0.036) 
Estimated ratio of 
UACR at week 26 to 
baseline: 
 
Liraglutide and 
placebo (0.87 vs. 
1.05; p=0.19) 
Imamura, 
et al. 
2013 
Non-
randomized,  
 
Single arm 
23 
Baseline eGFR:  
58.2 ml/min/1.73m2  
 
Baseline UPCR: 
 2.53 g/g  
12 months 
Liraglutide 
0.3mg/d 
titrated up 
to 0.9 mg/d 
Change in A1C from 
baseline to 12 
months:  
 
7.4% to 6.9% 
(p=0.035). 
 
 
Change in annual 
eGFR decline 
(ml/min/1.73m2) 
before and after 12 
months treatment:   
 
-6.6 to -0.33  
(p=0.003) 
 3 
 
Change in urinary 
protien (g/g Cr) from 
baseline to 12 
months:  
2.53 to 1.47 
(p=0.0015)  
 
 
Bouchi, et 
al. 2017 
Single-
center, 
randomized, 
open-label, 
comparative 
trial 
17 All patients had eGFR 
>60, but UACR >200 
mg/g at baseline: 
  
Liraglutide: 220 mg/g 
Control: 254 mg/g  
36 weeks Insulin 
treatment 
(control) vs. 
insulin + 
liraglutide 
0.3 mg/d 
Change in A1C from 
baseline to week 24:  
liraglutide vs. control  
(-0.7% vs. +0.2%; 
p=0.035)   
 
Change in UACR from 
baseline to week 24:  
 
liraglutide vs. control  
 4 
titrated to 
0.9 mg/d 
(liraglutide) 
(-129 mg/g vs. +56 
mg/g; p=0.016) 
SGLT2 inhibitor trials 
Kohan et 
al. 2014 
Randomized, 
double-
blind, 
placebo-
controlled 
trial 
252  
 
(139 
completed 
104 weeks 
of 
extension 
period) 
 
 
Baseline eGFR 30-59 
ml/min/1.73m2 in 
91.7% of all study 
patients 
 
Baseline UACR: 
Dapagliflozin (5 or 10 
mg): 73-79 mg/g 
Placebo: 67 mg/g  
 
24 weeks 
(some 
patients 
completed 
up to 104 
weeks) 
 
Dapagliflozin 
5 or 10 mg 
vs. placebo  
 
Change in A1C from 
baseline to week 24:  
 
Dapagliflozin 5 mg 
vs. placebo  
(-0.41% vs.  
-0.32%; p=0.561) 
 
Dapagliflozin 10 mg 
vs. placebo (-0.44% 
vs. -0.32%; p=0.435) 
Mean change in 
eGFR 
(ml/min/1.73m2) 
from baseline to 
week 24:  (No p-
value reported) 
 
Dapagliflozin 5 mg vs. 
placebo  
(-2.38 vs. -0.25) 
 
 5 
 
 
 
Change in FPG 
(mg/dL) from 
baseline to 24 
weeks: 
(No p-value 
reported): 
 
Dapagliflozin 5 mg 
vs. placebo  
(-5.2 vs. 8.4) 
 
Dapagliflozin 10 mg 
vs. placebo  
(-4.80 vs. -0.25) 
 
 
Proportion of 
patients experienced 
UACR >1800 mg/g 
during 104-week 
treatment period: 
(No p-value reported) 
 
Dapagliflozin 5 mg  
(10.8%) 
Dapagliflozin 10 mg 
 6 
Dapagliflozin 10 mg 
vs. placebo  
(-0.6 vs. 8.4) 
 
(9.5%) 
Placebo 
(13.3%)  
 
Number of patients 
shifting to lower 
UACR category at 
week 104: 
Dapagliflozin: 22.6% 
Placebo: 10.7% 
 
 
 
Yale et al. 
2013 
Randomized, 
double-
269 Baseline eGFR: 
39.4 ml/min/1.73m2 
26 weeks Canagliflozin 
100 or 300 
  
 7 
blind, 
placebo-
controlled 
trial 
 
Baseline UACR:  
30.0 mg/g 
mg vs. 
placebo 
Change in A1C from 
baseline to week 26: 
 
Canagliflozin 100 mg 
vs. placebo  
(-0.33% vs. -0.03%; 
p<0.05) 
 
Canagliflozin 300 mg 
vs. placebo  
(-0.44% vs. -0.03%; 
p<0.001) 
 
 
Change in eGFR 
(ml/min/1.73m2) 
from baseline to 
week 26: (No p-value 
reported) 
 
Canagliflozin 100 mg 
vs. placebo  
(-3.6 vs. -1.4) 
 
Canagliflozin 300 mg 
vs. placebo  
(-3.9 vs. -1.4) 
 
 
 8 
Change in FPG 
(mg/dL) from 
baseline to week 26: 
 
Canagliflozin 100 mg 
vs. placebo  
(-11.7 vs. 0.5; p=NS) 
 
Canagliflozin 300 mg 
vs. placebo  
(-14.9 vs. 0.5; p=NS) 
 
 
Percent reduction in 
UACR from baseline 
to week 26:  
(No p-values 
reported) 
 
Canagliflozin 100 mg 
vs. placebo  
(-29.9% vs. -7.5%) 
 
Canagliflozin 300 mg 
vs. placebo  
(-20.9% vs. -7.5%) 
 
 9 
Proportion of 
patients progressing 
from normal UACR 
to albuminuria from 
baseline to week 26:  
(No p-value reported)  
 
Canagliflozin 100 mg 
(5.1%) 
Canagliflozine 300 mg 
(8.3%) 
Placebo (11.8%) 
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Yale et al. 
2014 
Extension of 
Yale et al. 
2013 study 
229  
 
Baseline eGFR: 
39.4 ml/min/1.73m2 
 
Baseline UACR:  
30.0 mg/g 
52 weeks 
(26-week 
extension 
of 
previous 
Yale et al. 
2013 
study) 
Canagliflozin 
100 or 300 
mg vs. 
placebo 
Change in A1C from 
baseline to week 52: 
 
Canagliflozin 100 mg 
vs. placebo  
(-0.19% vs. 0.07%;  
95% CI, -0.53 to 
0.001) 
 
Canagliflozin 300 mg 
vs. placebo  
(-0.33% vs. 0.07%;  
95% CI, -0.68 to -
0.14) 
 
Change in eGFR 
(ml/min/1.73m2) 
from baseline to 
week 52: 
 
Canagliflozin 100 mg 
vs. placebo  
(-2.1 vs. -1.6; 95% CI,  
-2.8 to 1.7) 
 
Canagliflozin 300 mg 
vs. placebo  
(-4.0 vs. -1.6;  
95% CI, -4.6 to -0.3) 
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Change in FPG 
(mmol/L) from 
baseline to week 52: 
 
Canagliflozin 100 mg 
vs. placebo  
(-0.1 vs. 0.5;  
95% CI, -1.5 to 0.2) 
 
Canagliflozin 300 mg 
vs. placebo  
(-0.3 vs. 0.5;  
95% CI, -1.7 to 0.1) 
 
 
Percent change in 
UACR from baseline 
to week 52:  
(No p-value reported) 
 
Canagliflozin 100 mg 
vs. placebo  
(-16.4% vs. 19.7%) 
 
Canagliflozin 300 mg 
vs. placebo  
(-28.0% vs. 19.7%) 
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 Proportion of 
patients progressing 
from normal UACR 
to albuminuria from 
baseline to week 52: 
  
Canagliflozin 100 mg 
(10.3%) 
Canagliflozine 300 mg 
(14.7%) 
Placebo (17.%) 
 
Heerspink 
et al. 
2017 
Secondary 
analysis of 
patients 
230 
 
Baseline eGFR: 
86.5-91.1 
ml/min/1.73m2 
2 years Canagliflozin 
100 or 300 
mg vs. 
Change in A1C for 
subgroup with UACR 
Hazard ratio (HR) for 
30% decline in eGFR 
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 with UACR 
≥30 mg/g 
enrolled in 
previous 
randomized 
trail   
 
 
Baseline UACR: 
Canagliflozin 100 mg: 
56.5 mg/g 
 
Canagliflozin 300 mg:  
75.2 mg/g 
 
Glimepiride:  
60.1 mg/g 
 
glimepiride 
titrated up 
to 8 mg  
≥30 mg/g not 
reported 
 
 
(canagliflozin vs. 
glimepiride): 
 
Canagliflozin 100 mg: 
HR=0.37; p=0.03 
 
Canagliflozin 300 mg: 
HR=0.69; p=0.33 
 
 
Percent reduction in 
UACR (canagliflozin 
vs. glimepiride): 
 
Canagliflozin 100 mg: 
 14 
-31.7% (p=0.01) 
 
Canagliflozin 300 mg: 
-49.3% (p<0.001) 
 
Barnett 
et al. 
2014 
Randomized, 
double-
blind, 
placebo-
controlled 
trial 
 
Included 
subgroups of 
patients 
374 
patients 
with CKD 
stage 3 
Baseline eGFR (Stage 
3 CKD patients):  
44.9 ml/min/1.73m2 
 
 
52 weeks Empagliflozin 
25 mg or 
placebo 
Change in A1C from 
baseline to week 24: 
 
Empagliflozin vs. 
placebo  
(-0.37% vs. 0.05; 
p<0.0001) 
 
Change in A1C from 
baseline to week 52: 
Change in UACR 
(mg/g) from baseline 
to week 52: 
 
Empagliflozin vs. 
placebo  
(-183.8; p=0.0031); 
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with CKD 2-4 
(subgroup 
analysis 
available for 
each CKD 
stage) 
 
Empagliflozin vs. 
placebo  
(-0.32% vs. 0.12; 
p<0.0001) 
 
 
Change in FPG 
(mmol/L) from 
baseline to week 24: 
 
Empagliflozin vs. 
placebo  
(-0.5 vs. 0.6; 
p<0.0001) 
Proportion of 
patients progressing 
from normal UACR 
to microalbuminuria: 
(No p-value reported) 
 
Empagliflozin vs. 
placebo (12.2% vs. 
22.2%) 
 
Proportion of 
patients progressing 
from 
microalbuminuria to 
macroalbuminuria: 
 16 
 
Change in FPG 
(mmol/L) from 
baseline to week 52: 
 
Empagliflozin vs. 
placebo  
(-0.4 vs. 0.3; 
p=0.0037) 
(No p-value reported) 
 
Empagliflozin vs 
placebo (2.0% vs. 
11.4%) 
A1C= hemoglobin A1C; CKD= chronic kidney disease; eGFR= estimated glomerular filtration rate; FPG= fasting plasma glucose; UACR= 
Urinary albumin-to-creatinine ratio; UPCR= Urine protein-to-creatinine ratio 
 
